# A Study of Anti-VEGFR-3 Monoclonal Antibody IMC-3C5 in Subjects With Advanced Solid Tumors

> **NCT01288989** · PHASE1 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 44 (actual)

## Conditions studied

- Neoplasms

## Interventions

- **BIOLOGICAL:** IMC-3C5

## Key facts

- **NCT ID:** NCT01288989
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-03
- **Primary completion:** 2014-07
- **Final completion:** 2014-07
- **Target enrollment:** 44 (ACTUAL)
- **Last updated:** 2019-06-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01288989

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01288989, "A Study of Anti-VEGFR-3 Monoclonal Antibody IMC-3C5 in Subjects With Advanced Solid Tumors". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01288989. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*